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A Common Polymorphism in HIBCH
Influences Methylmalonic Acid Concentrations
in Blood Independently of Cobalamin
Anne M. Molloy,1,* Faith Pangilinan,2 James L. Mills,3 Barry Shane,4 Mary B. O’Neill,2
David M. McGaughey,2 Aneliya Velkova,2 Hatice Ozel Abaan,2 Per M. Ueland,5 Helene McNulty,6
Mary Ward,6 J.J. Strain,6 Conal Cunningham,7 Miriam Casey,7 Cheryl D. Cropp,8,9 Yoonhee Kim,8,10
Joan E. Bailey-Wilson,8 Alexander F. Wilson,8 and Lawrence C. Brody2,*
Methylmalonic acid (MMA) is a by-product of propionic acid metabolism through the vitamin B12 (cobalamin)-dependent enzyme
methylmalonyl CoA mutase. Elevated MMA concentrations are a hallmark of several inborn errors of metabolism and indicators of
cobalamin deficiency in older persons. In a genome-wide analysis of 2,210 healthy young Irish adults (median age 22 years) we identified
a strong association of plasma MMAwith SNPs in 3-hydroxyisobutyryl-CoA hydrolase (HIBCH, p ¼ 8.423 1089) and acyl-CoA synthe-
tase familymember 3 (ACSF3, p¼ 3.483 1019). These loci accounted for 12% of the variance inMMA concentration. Themost strongly
associated SNP (HIBCH rs291466; c:2T>C) causes a missense change of the initiator methionine codon (minor-allele frequency ¼ 0.43)
to threonine. Surprisingly, the resulting variant, p.Met1?, is associated with increased expression of HIBCHmRNA and encoded protein.
These homozygotes had, on average, 46% higher MMA concentrations than methionine-encoding homozygotes in young adults with
generally low MMA concentrations (0.17 [0.14–0.21] mmol/L; median [25th–75th quartile]). The association between MMA levels and
HIBCH rs291466 was highly significant in a replication cohort of 1,481 older individuals (median age 79 years) with elevated plasma
MMA concentrations (0.34 [0.24–0.51] mmol/L; p ¼ 4.0 3 1026). In a longitudinal study of 185 pregnant women and their newborns,
the association of this SNP remained significant across the gestational trimesters and in newborns. HIBCH is unique to valine catabolism.
Studies evaluating flux through the valine catabolic pathway in humans should account for these variants. Furthermore, this SNP could
help resolve equivocal clinical tests where plasma MMA values have been used to diagnose cobalamin deficiency.Introduction
Methylmalonic acid (MMA) is a by-product of the reaction
catalyzed by methylmalonylCoA mutase (MUT), one of
two enzymes in mammals that use vitamin B12 (cobal-
amin) as a cofactor.1 This mitochondrial enzyme plays an
important role in the metabolism of odd-chain fatty acids
and the branched-chain amino acids valine, leucine, and
isoleucine. Catabolism of these molecules produces meth-
ylmalonylCoAwhich is converted to succinylCoA viaMUT
activity. If MUT does not function effectively, the MMA
concentration in blood increases. Rare high-penetrance
mutations in MUT (MIM: 609058) or in enzymes affecting
the transport or synthesis of 50adenosylcobalamin cause a
number of inborn errors of metabolism characterized by
methylmalonic acidemia.2 However, there are currently
no data to suggest that genetic variation in MUT deter-
mines plasma MMA levels outside of rare inborn errors of
metabolism. Furthermore, there are no data on the relative
contributions of branched-chain amino acid or fatty acid
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circulating MMA levels are observed in individuals with
severe mutations in ALDH6A1 (MIM: 603178), which
encodes methylmalonate semialdehyde dehydrogenase,3
and ACSF3 (MIM: 614245), which encodes a mitochon-
drial AcylCoA synthetase considered to have malonylCoA
and methylmalonyl CoA activities,4,5 and in mitochon-
drial depletion diseases such as succinate Co-A ligase defi-
ciency due to mutations of mitochondrial SUCLG1 (MIM:
611224).6
In contrast to diseases of newborns that result in
elevated MMA concentration, cobalamin deficiency is
relatively common among the elderly; estimates of defi-
ciency range from 6% to over 40% in this population.7–11
Untreated cobalamin deficiency can lead to megaloblastic
anemia or irreversible neurological damage.12 The MUT
enzyme is extremely sensitive to cobalamin deficiency,
and circulating MMA concentration is regarded as a
sensitive and specific marker of cobalamin status, such
that plasma concentrations within the normal reference
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concentrations >0.5 mmol/L almost invariably indicate
deficiency.13,14 However, MMA concentration is influ-
enced by age and renal impairment.15–17 Many older per-
sons have marginally elevated MMA concentrations in
the range of 0.27–0.37mmol/L.18 This elevation is not asso-
ciated with the status of other cobalamin biomarkers, such
as the serum total cobalamin or plasma homocysteine.
Circulating MMA concentrations in excess of 0.37 mmol/L
are used to define inadequate cobalamin status;14,19–21
nevertheless, in one study of older subjects, known deter-
minants of MMA levels (age, plasma creatinine, and
plasma total cobalamin) accounted for less than 17% of
the variation in this trait.16 Several reports have demon-
strated transiently high MMA concentration in plasma
and urine of neonates up to 6 months old,22 but it remains
unclear whether this is related to low cobalamin status or
whether other processes involved in MMA handling that
are independent of vitamin B12 function are not fully
developed.23 Identification of genetic factors that influ-
ence circulating MMA concentration in healthy individ-
uals would greatly help in interpreting MMA levels that
are elevated but of unknown clinical significance.
To identify loci that influence the plasma MMA concen-
tration in healthy individuals, we conducted a genome-
wide association study (GWAS) in a cohort of healthy
young Irish adults aged between 18 and 28 years. Our
study of this ethnically and environmentally homoge-
neous group identified variants that were also associated
with circulating MMA levels in two Irish replication co-
horts (older adults and pregnant women). We present evi-
dence that the functional variant underlying the strongest
association signal acts at the level of transcription.Material and Methods
Recruitment of the Subjects for the GWAS
The Trinity Student Study (TSS) population has been described
previously.24–26 The cohort was established over one academic
year (2003–2004) for the purpose of exploring the heritability of
quantitative traits. A total of 2,524 eligible students attending the
University of Dublin, Trinity College (TCD) were invited to partic-
ipate in the study. Eligibility criteria includedbeingbetween18 and
28 years old, having no current serious medical condition, and be-
ing of Irish ethnicity based on geographic origins of grandparents.
All participants gave a non-fasting 30mL venous blood sample and
completed a health and lifestyle questionnaire in which informa-
tion on age, gender, height, weight, medical history and medica-
tions, smoking, alcohol intake, and dietary habits was collected.
Detailed supplement and fortified food intake data were addition-
ally collected as part of the questionnaire. Participants were paid
a modest honorarium for completing the study. Fifteen students
did not return a questionnaire and were excluded. One student
was found to have participated twice and the second blood sample
and questionnaire were excluded. Samples from 2,508 participants
with questionnaire data went forward for metabolite analysis and
DNA extraction. Ethical approval was obtained from the Dublin
Federated Hospitals Research Ethics Committee, which is affiliated
with TCD, and was reviewed by the Office of Human Subjects870 The American Journal of Human Genetics 98, 869–882, May 5, 2Research at the NIH. Written informed consent was obtained
from the participants when they enrolled.Recruitment of the Older Adult Replication Cohort
The replication cohort consisted of 5,186 subjects recruited as part
of the Trinity, Ulster, Department of Agriculture (TUDA) Study, a
study of older Irish adults designed to investigate nutritional
factors, related gene-nutrient interactions, and a range of health
and lifestyle factors in the development of chronic diseases of
aging in non-institutionalized adults. Recruitment was carried
out in Dublin and in Northern Ireland between September 2008
and December 2012 from either hospital outpatient clinics or
the community, and subjects were deemed eligible if they were
aged over 60 years, of Irish parents, and without a prior diagnosis
of dementia. Detailed health, lifestyle, and clinical information,
including medication use, smoking status, physical activity, and
vitamin supplement usage, was obtained for all subjects. Further
details of the cohort have been published previously.27 Cobalamin
statuswas assessedwithboth serumtotal cobalaminandserumhol-
otranscobalamin (holoTC) measurements on all subjects. Plasma
MMAconcentrationwasmeasuredona subsetof 1,511 individuals,
based on their cobalamin status. All individuals who had either
serum cobalamin % 148 pmol/L or holoTC % 30 pmol/L (n ¼
856) and a random (generated fromsubject ID) selectionof individ-
uals with both serum cobalamin and holoTC above the respective
cut-offs (n ¼ 655) were assigned to plasma MMA analysis in order
to perform a quantitative trait analysis of plasma MMA concen-
tration on the pooled samples. The studywas conducted according
to the guidelines in the Declaration of Helsinki, and ethical
approval was granted by the relevant authorities in each jurisdic-
tion: the Research Ethics Committee of St. James’s Hospital and
The Adelaide and Meath Hospital, Dublin, and the Office for
Research Ethics Committees, Northern Ireland (ORECNI; reference
08/NI/RO3113) with corresponding approvals from The Northern
and Western Health and Social Care Trusts, Northern Ireland.
Participants in all studies provided written informed consent at
the time of enrollment.Recruitment of the Longitudinal Pregnancy Cohort
A total of 201 women were recruited between 2004 and 2005 at
their first ante-natal visit to the Coombe Women and Infants
University Hospital in Dublin, Ireland. They agreed to participate
in a longitudinal study involving collection of non-fasting blood
samples at 14 weeks, 24 weeks, and 34 weeks of pregnancy and
a cord blood sample upon delivery. Although time points are
missing for some women, and cord blood samples were only avail-
able from 117 deliveries, all available samples were retained for
analysis. All participants had uncomplicated pregnancies and
gave birth to infants free of any major health issues. Participants’
blood samples were used to extract genomic DNA for genotyping
and to measure the concentrations of circulating metabolites in
plasma. All participants gave written informed consent, and
ethical approval was granted by the Coombe Women and Infants
University Hospital Research Ethics Committee and the Office of
Human Research Subjects at the NIH.
Samples for the TSS GWAS discovery cohort and for both repli-
cation cohorts were rendered anonymous prior to analysis.Metabolite Analysis
Non-fasting blood samples were collected into EDTA, lithium hep-
arin, and clotting tubes. Samples for MMA, cobalamin, holoTC,016
and total homocysteine (tHcy) analysis were processed within
3 hr of collection and were stored below 80C, until analyzed.
Plasma MMA concentration was measured by Bevital, Bergen,
with gas chromatography mass spectroscopy.28 Plasma MMA
measures were obtained for 2,483 of 2,508 participants. Missing
plasma MMA values were due to an insufficient sample for the
initial measure or its repeat in the case of a high coefficient of
variation. Serum cobalamin was measured with colistin-resistant
L. delbreuckii by microbiological assay.29 HoloTC and plasma ho-
mocysteine were measured via automated AxSym-based immuno-
fluorescence methods.30,31 Inter-assay CVs for all methods were
as follows: MMA, 8.1%; serum total cobalamin, 10.6%; serum
holoTC, 9.4%; plasma homocysteine, 2.2%. Circulating MMA
concentrations are reported to be stable during long-term storage
below 40C and are not affected by recent food intake.32Blood DNA Extraction and Genotyping of the TSS
We extracted genomic DNA from all samples by using QIAGEN
QIAamp DNA Blood Mini Kits. In the TSS, eighteen samples
with low quantity DNA were excluded and 2,490 samples were
sent for genotyping. Genome-wide SNP genotyping was con-
ducted at the Center for Inherited Disease Research (CIDR) in
Baltimore with Illumina 1M HumanOmni1-Quad_v1-0_B chips.
High-quality genotypes were obtained on 2,438 study samples,
14 randomly selected duplicates, and HapMap controls. The blind
duplicates had a concordance rate of 99.997%, and the HapMap
samples had a 99.71% concordance rate.Genotyping Quality Control and Data Preparation for
GWAS
In a preliminary analysis for anomalies, ten subjects were excluded
because of gender discrepancy between self-report and genotypes
(n¼ 7) and abnormal sex chromosomes (n¼ 3; one XYYmale and
two XX/XOmosaic females). 16 subjects with incomplete anthro-
pometric data were removed. Siblings from 77 families reported
entry into the study. These included two siblings from 74 families
and three siblings from three families. Pair-wise tests for related-
ness and population stratification within all the genotyped
samples were performed with PLINK v.2,33 and a relatively inde-
pendent but otherwise random subset of 25,718 SNPs (all selected
SNPs had pair-wise intermarker linkage disequilibrium [LD] r2 <
0.04 for both short and long-range blocks of SNPs, minor-allele
frequency [MAF] > 0.1 and genotype call rates > 0.99). These
analyses confirmed the self-reported sibling relationships, and
identified additional pairs of individuals who appeared closely
related, to the level of 1st cousins. In order to reduce effects of relat-
edness, only one individual from each family was retained. In to-
tal, 175 individuals were removed (80 siblings and 95 1st cousins).
Finally, principal components (PC) analysis was performed with
the EIGENSOFT 3.0 software,34 and this same low-LD subset of
25,718 SNPs to detect potential population stratification. Scores
from the first two PCs (PC1 and PC2) were examined, and two
samples were detected as outliers from the main-population clus-
ter of samples, suggesting that their ancestry might be different
than that of the remainder of the cohort (6 SD away from the
mean). These two samples were excluded from further analyses.
Otherwise, the sample set was remarkably homogeneous for ge-
netic variation, consistent with accurate self-report of participants
and their Irish ethnicity. No significant evidence of population
stratification (no significant principal components) was observed
in these data after dropping the two outlier samples. As such, noThe Amadjustment was made for stratification in the association analyses.
The full data preparation process resulted in a final dataset of 2,235
study samples in the GWAS association analysis.
Quality control assessment was performed based on genotyping
data for 1,008,829 SNPs. SNPs and/or samples were excluded in
two stages. In stage 1, SNPs that had less than 95% call rates
were dropped and then samples with less than 97% call rates or
that showed cryptic relatedness were dropped (57 samples total).
In stage 2, SNPs were dropped that had (1) less than 98% call
rate, (2) Mendelian errors when we used Hapmap trios, (3) discor-
dant markers when we used Hapmap controls, and (4) discordant
markers from one or more pairs based on study duplicates. SNPs
with extreme deviation from the Hardy-Weinberg equilibrium
(p < 1 3 104) were flagged for future reference and remained in
the analysis. We also measured LD in our dataset and examined
LD plots by using the HaploView program.35 The data were
checked for batch effects with several methods from published
GWAS quality control guidelines.36 No significant batch effects
were detected. These methods included (1) descriptive statistics
per batch (average MAF, average genotyping call rate across all
SNPs for each plate) and (2) basic allelic chi-square association
test (1 df) using the ‘‘–loop-assoc’’ command in PLINK; results
compared each batch to the others and at random (median
p value, number of significant results at p value thresholds
of < 1 3 103 and < 1 3 104). The final dataset contained
758,443 genotyped SNPs (3,512 of these SNPs had Hardy-Wein-
berg equilibrium p < 104) after the exclusion of monomorphic
and low MAF SNPs (MAF < 0.01) for 2,235 samples. TSS genotype
and phenotype data have been deposited in dbGAP ([dbGAP:
phs000789.v1.p1] Collaborative Study of Genes, Nutrients and
Metabolites [CSGNM]).Imputation of SNPs in the TSS
TheMACH1.0 program37 was usedwith a set of 757,533 post-qual-
ity-control autosomal SNPs to impute ungenotyped SNPs with the
HapMap II CEU (CEPH; Utah residents with ancestry from north-
ern and western Europe) reference panel, resulting in 2,350,751
imputed genotypes per person after quality control, such that
imputed SNPs were only retained for analysis if the squared corre-
lations between imputed and actual genotypes for a set of masked
genotypes (R2) was greater than 0.5. We used 200 individuals for
estimating model parameters with 100 iterations for the Monte
Carlo procedure by using all available haplotypes for each update,
and then we imputed all the SNPs in the HapMap II CEU reference
panel.GWAS Statistical Analysis
Plasma MMA results were available for 2,210 of the 2,235 samples
that passed the SNP genotype-based quality control analyses, so
the discovery analysis for plasma MMA concentration relates to
these 2,210 individuals. Standard descriptive statistics, including
frequency distribution of MMA values, median, mean, theoretical
versus sample quantile Q-Q plots, and measurements of skewness
and kurtosis, were performed on the observed MMA measures
both with and without transformation. The distribution of the
MMAmeasurements in the TSS study participants deviated signif-
icantly from a normal distribution, and a log10 transformation was
used to normalize the MMA values for the linear regression ana-
lyses. Therefore, for the GWAS, genotyped and imputed autosomal
SNPs that passed quality control were tested for association with
the log10-transformed MMA values, adjusted for age and sex.erican Journal of Human Genetics 98, 869–882, May 5, 2016 871
Figure 1. Genome-wide Analysis of
Plasma MMA Levels in the TSS Cohort
At the genome-wide level, HIBCH
rs291466 is the SNP most significantly
associated with log10-transformed plasma
MMA concentration in the TSS cohort of
2,210 young, healthy Irish adults.
(A) A Manhattan plot of the log10-trans-
formedMMAGWAS of 758,443 genotyped
SNPs. Thehorizontal blue line indicates the
genome-wide significance threshold (p ¼
53 108). The horizontal red line indicates
the suggestive significance threshold (p ¼
1 3 1005). The two strongest signals are
found in HIBCH and ACSF3.
(B) Q-Q plot of p values obtained for the
log10-transformed MMA GWAS.
(C) Distribution of MMA plasma levels for
each HIBCH rs291466 genotype group.
Means and 95% confidence intervals for
each genotype group’s MMA levels are
shown (ANOVA p < 0.0001).
(D) Values for plasma MMA plotted by
serum cobalamin for each HIBCH rs291466
genotype group of young adults. Cobal-
amin data were categorized by groups in
ascending order of 100 pmol/L. Median
MMA values were calculated within each
grouped category. Line graphs were plotted
asmedianMMA against median cobalamin
within each group.Other factors known to influence MMA levels (renal function,
serum cobalamin) were not adjusted for given that renal function
and cobalamin absorption are not compromised in this young,
healthy cohort. In the simple linear regression model, the associ-
ation test of each marker was performed with PLINK v.2 under
the assumption of an additive genetic model (i.e., number of
minor alleles, 0, 1, and 2). The genomic control lambda was
0.991 for both the untransformed trait and the transformed trait
(Table S1), and results using the transformed trait are reported
here. (See Figure 1 and Figures S1–S3 for results using the trans-
formed MMA levels in the analysis of the genotyped SNPs and
in the complete set of genotyped plus imputed SNPs, and see Table
S2 for a list of SNPs for which missense or nonsense variants were
significantly associated with MMA levels.) The contributed varia-
tion of each marker to MMA concentration was calculated by
regression R squared (R2). Manhattan plots and Q-Q plots were
generated with R scripts written within our institution. To further
evaluate the distribution of p values obtained in this GWAS, Q-Q
plots without the markers on chromosomes 2 and 16 were also
generated, to remove the effect on the plots of these extremely sig-
nificant SNPs (Figures S1 and S3). Genomic-control lambda values
were calculated for each analysis (Table S2).Genotyping in the Replication Cohorts and Statistical
Analysis of Metabolites in the TSS, TUDA, and
Longitudinal Pregnancy Cohorts
All 5,186 TUDA samples were genotyped for HIBCH (MIM:
610690) rs291466 (GenBank: NM_014362.3:c.2T>C) and ACSF3
rs1054747 ([GenBank: NM_001127214.3] c.*231G>A) by LGC
Genomics (Herts, UK) with KASP genotyping chemistry. The call
rates were 98.9% and 98.0%, respectively. Duplicate samples
(2%) were included, as well as the addition of a single control
sample to every plate. Concordance for all duplicates was >99%.872 The American Journal of Human Genetics 98, 869–882, May 5, 2In this sample, measures of plasma MMA data were available for
1,511 individuals; 1,481 of these had genotype data for HIBCH
rs291466 and 1,458 of these had genotype data for ACSF3
rs1054747. The replication analysis therefore relates to these
1,481 individuals. All 201 pregnant mothers and 117 cord bloods
were genotyped for HIBCH rs291466 and ACSF3 rs1054747 by
detection of allele-specific extension products via matrix-assisted
laser desorption/ionization and time-of-flight (MALDI-TOF) mass
spectrometry (Sequenom). For both SNPs, the call rates were
94% for the mothers andR96% for the newborns, and genotypes
were 100% concordant for the >12% of samples that were re-
plated and independently typed. The final replication analyses
involved 185 mothers and 110 newborns with valid HIBCH
rs291466 genotype and MMA data, and 182 mothers and 113
newborns with valid ACSF3 rs1054747 genotype and MMA data.
In the TSS, direct genotyping of HIBCH rs291466 yielded calls
for 2,208 of the 2,210 subjects with MMA data who were included
in the GWAS. Similar to the TSS data, distribution of the MMA
measurements in the TUDA study participants and in the longi-
tudinal pregnancy cohort did not approximate normal distribu-
tions, and a log10 transformation was used to approximately
normalize the MMA values for the linear regression analyses.
HIBCH rs291466 was tested for association with the transformed
unadjusted MMA values in the TUDA cohort and in the longitudi-
nal pregnancy cohort. These association tests were performedwith
PLINK v.2 by simple linear regression and under the assumption of
an additive genetic model as described above for the TSS GWAS.
Data for cobalamin biomarkers in the TSS and the replication
datasets were not normally distributed. For Tables 1–3, all data
are presented as medians with 25th and 75th percentile values (in-
terquartile intervals; IQI). Comparisons of data across the three
HIBCH rs291466 genotype groups were carried out with the non-
parametric Kruskal-Wallis one-way ANOVA by ranks for three or
more independent groups. p values < 0.05 were considered016
significant and represent a difference across the three genotype
groups, without specifying exactly which groups are different.
GWAS Catalog Query
To determine whether the lead SNPs identified in this study might
have been previously associated with any disease phenotype or
other trait, we searched the National Human Genome Research
Institute and the European Bioinformatics Institute (NHGRI-EBI)
GWAS Catalog.38 No entries were found for HIBCH rs291466
or ACSF3 rs1054747, or for SNPs in LD (r2 > 0.8, 1000 Genomes
EUR super population) with them (n ¼ 40 and n ¼ 84,
respectively).
Analysis of mRNA Abundance
Because HIBCH rs291466 and ACSF3 rs1054747 are coding SNPs,
RNA-seq data can be used to quantitate transcripts carrying each
allele. Two approaches were used to evaluate whether mRNA
abundance is influenced by the SNPs associated with plasma
MMA concentration. First, RNa-seq data from heterozygotes
were used to determine how much HIBCH or ACSF3 transcript
was expressed from each allele. Second, individuals were divided
into groups based on HIBCH rs291466 or ACSF3 rs1054747 geno-
types to compare the overall abundance of these transcripts.
First, to calculate the relative ratios of the T (Met) and C (?)
rs291466 alleles, the raw BAM files for the 211 HIBCH rs291466
heterozygous individuals in the Geuvadis RNA Sequencing Proj-
ect39 were downloaded. Samtools’ mpileup was used to find the
number of reads with T (Met) or C (?) alleles expressed in the lym-
phoblastoid cell lines generated from each individual and the data
were plotted in R. To determine the statistical significance of the
T (Met) and C (?) allele abundance in the RNA-seq data, a Pearson’s
chi-square test was performed.
Second, we checked relative mRNA expression between the
HIBCH rs291466 genotype groups by using RPKM (reads per
kilobase of transcript per million reads mapped) scores from the
GD462.GeneQuantRPKM.50FN.samplename.resk10.txt.gz file39
and plotting in R (v.2.15.1). Significance was calculated with
anova() from the base package in R. To confirm these results,
Genotype-Tissue Expression (GTEx, v.4) data were similarly
analyzed.40 HIBCH microarray expression scores in lymphoblas-
toid tissue were re-plotted by HIBCH rs291466 genotype group
with ggplot() from the ggplot2 package (0.9.2.1) in R. For display
purposes, HapMap CEU (n ¼ 60), YRI (Yoruba in Ibadan, Nigeria;
n ¼ 60), and JPT/CHB (Japanese in Tokyo, Japan/Han Chinese in
Beijing, China; n ¼ 89) individuals were combined into a single
group for analysis. Significance was calculated with anova() from
the base package in R. These analyses were repeated for ACSF3
rs1054747.
Western Blotting and Subcellular Localization of
HIBCH
To determine whether HIBCH rs291466 grossly alters protein
levels, western blotting of whole-cell extracts was performed.
Five different Coriell cell lines (GM18621, GM18961, GM17443,
GM17449, GM17454) with the TT (Met/Met) genotype and four
different Coriell cell lines (GM12814, GM17438, GM17456,
GM17460) with the CC (?/?) genotype were analyzed. Whole-
cell extracts were prepared by lysing cells in RIPA buffer (10 mM
Tris [pH 7.4]; 150 mM NaCl; 5 mM EDTA [pH ¼ 8]; 1% Triton
X-100; 0.1% sodium deoxycholate; 0.1% SDS) supplemented
with protease inhibitor cocktail (Sigma). Western blotting was per-The Amformed with the Odyssey LI-COR Imaging system. In brief, nitro-
cellulose membranes were blotted in Odyssey blocking buffer for
1 hr, followed by 1 hr incubation with HIBCH Prestige antibody
(Sigma), HIBCH antibody (Proteintech), or proliferating cell
nuclear antigen (PCNA [MIM: 176740]) antibody (Santa Cruz),
which was used as a loading control. After extensive washing,
the membranes were incubated with Odyssey donkey anti-rabbit
IRDye-800 or Odyssey donkey anti-mouse IRDye-680 for 0.5 hr.
Western blot membranes were quantified on an Odyssey LI-COR
Imaging system. HIBCH signal (green channel) was normalized us-
ing PCNA signal (red channel) as an internal control. Both HIBCH
and PCNA signals were derived from a single western blot. Three
independent experiments were performed. A representative west-
ern blot is shown in Figure 3D.
Similarly, to determine whether HIBCH rs291466 influences
the subcellular localization of HIBCH, western blotting of cyto-
plasmic, mitochondrial, and nuclear fractions was performed.
Mitochondrial import was assessed via western blot after perfor-
mance of subcellular fractionation (Qproteome Cell Compart-
ment Kit, QIAGEN). Fraction purity was assessed with a control
antibody specific for the mitochondrial compartments.Results
GWAS Discovery Cohort
We identified two regions of genome-wide significant as-
sociation with log10-transformed MMA values (Figures 1A
and 1B). The strongest association was observed with
HIBCH rs291466 (p ¼ 8.42 3 1089), a directly typed
SNP on chromosome 2 accounting for 9.9% of the total
variance. This SNP is a non-synonymous polymorphism
(c.2T>C) resulting in a methionine to a presumed threo-
nine change in the translational start codon of the en-
coded protein, p.Met1? (note: the coding impact of this
SNP in the initiator methionine is unknown and we
therefore refer to this isoform as ‘‘?’’). Although T (Met)
is the ancestral allele (based on the allele present in the
great apes), the C (?) allele is more common in the stud-
ied population. The median plasma MMA concentration
for the corresponding CC (?/?) homozygotes was 46%
higher than the TT (Met/Met) homozygotes (Table 1).
This effect was independent of biochemical markers
of cobalamin status, including serum total cobalamin,
holoTC, and plasma homocysteine (Figures 1C and 1D
and Table 1).
The second region of genome-wide significance was in
the ACSF3 region on chromosome 16, consistent with pre-
vious studies showing that severe mutations in ACSF3
affect MMA concentrations. Patients with these mutations
were found to have combinedmalonic andmethylmalonic
aciduria (CMAMMA [MIM: 614265]).4,5 The described pa-
tients are homozygous or compound heterozygous for
rare coding changes inACSF3 and have plasmaMMA levels
an order of magnitude higher than normal. The strongest
ACSF3 signal among the genotyped SNPs (rs1054747,
MAF ¼ 0.05, p ¼ 3.48 3 1019) fell in the 30 UTR of the
gene and accounted for 2.1% of the total variance. Just
three homozygotes carrying the minor A allele wereerican Journal of Human Genetics 98, 869–882, May 5, 2016 873
Table 1. Subject Characteristics of the TSS Discovery Cohort, with Participants Grouped by HIBCH rs291466 Genotype
Characteristic
Alla CC (?/?) CT (?/Met) TT (Met/Met)
Kruskal-Wallis Testc
p ValueMedian (IQIb) Median (IQIb) Median (IQIb) Median (IQIb)
No. of Individuals 2,208 721 1,065 422 –
Sex (M/F) 907/1,301 299/422 442/623 166/256 –
Age (years) 22.0 (21.0–24.0) 22.0 (21.0–23.0) 22.0 (21.0–24.0) 23.0 (21.0–24.0) 0.008
Body Mass Index (kg/m2) 22.6 (21.0–24.4) 22.5 (21.0–24.5) 22.7 (21.1–24.5) 22.5 (20.8–24.4) 0.454
Creatinine (mmol/L) 64.8 (56.4–74.6) 65.1 (56.7–75.4) 64.7 (56.4–74.4) 64.1 (56.3–74.1) 0.586
Hemoglobin (g/dL) 14.1 (13.1–15.2) 14.1 (13.2–15.3) 14.1 (13.1–15.2) 14.1 (13.1–15.4) 0.677
Urea (mmol/L) 4.30 (3.70–5.10) 4.40 (3.70–5.13) 4.30 (3.60–5.10) 4.20 (3.50–5.00) 0.030
Plasma cobalamin (pmol/L) 306 (231–411) 307 (231–421) 305 (232–405) 305 (230–411) 0.675
holoTC (pmol/L) 53.7 (39.1–72.2) 54.1 (39.5–72.8) 53.2 (38.9–71.4) 55.4 (39.5–73.3) 0.388
Homocysteine (mmol/L) 8.13 (7.00–9.62) 8.17 (6.99–9.61) 8.17 (7.08–9.61) 7.92 (6.83–9.75) 0.319
MMA (mmol/L) 0.17 (0.14–0.21) 0.19 (0.16–0.24) 0.16 (0.14–0.20) 0.13 (0.11–16) < 0.0001d
M, male; F, female.
aValid HIBCH rs291466 genotypes were obtained for 2,208 of the 2,210 TSS subjects in the GWAS study.
bIQI (inter-quartile interval) represents the 25th–75th percentile.
cThe non-transformed data were compared with the Kruskal-Wallis one-way ANOVA by ranks for three or more independent groups; p < 0.05 was considered
significant.
dThe association test for this SNP was also performed by simple linear regression with PLINK v.2 and under the assumption of an additive genetic model (number of
minor alleles: 0, 1, and 2). p ¼ 1.95 3 1087 was obtained for the unadjusted log10-transformed data.detected, but GA heterozygotes had a higher plasma MMA
concentration than GG homozygotes (0.22 mM versus
0.18 mM). This SNP is linked (D0 ¼ 1, r2 > 0.92) to
SNPs in two adjacent non-coding RNAs (LINC00304,
LOC400558) and the nearby cadherin 15 (CDH15)
gene, but ACSF3 remained the best candidate gene for
containing the causal variant because of its biological
relevance. The 40 SNPs in high LD (r2 R 0.95) with
ACSF3 rs1054747 are intronic or intergenic, and the func-
tional variant responsible for influencing MMA concentra-
tion remains unidentified. No regions of significance were
observed in chromosome 6, the location ofMUT. Next, we
focused our efforts on performing replication analyses in
two independent populations and undertaking functional
characterization studies.
Older Adult Replication Cohort
Because MMA concentration is known to increase signifi-
cantly with age, it was possible that the impact of this
genotype would disappear in the elderly. To test this
hypothesis, we genotyped HIBCH rs291466 in 1,481 older
individuals in whom we had measured plasma MMA
levels and other biochemical markers of cobalamin status
(Table 2). As in our young adults, the genotype effect for
HIBCH rs291466 on the transformedMMA data was highly
significant (p ¼ 4.013 1026), and the genotype effect was
discernible even when these subjects were categorized into
three groups by age or by glomerular filtration rate (GFR, a
measure of renal function; Figures 2A and 2B). Of note, this
effect was independent of cobalamin status using either
holoTC or total cobalamin as the serum indicators (Figures874 The American Journal of Human Genetics 98, 869–882, May 5, 22C and 2D) and was also independent of plasma homocys-
teine, a metabolic biomarker of cobalamin deficiency and a
metabolite that, like MMA, is sensitive to reduced renal
function.
The effect of ACSF3 rs1054747 on log10-transformed
MMA levels was similarly assessed in this population of
older Irish adults, resulting in replication of the originally
observed effect (p ¼ 0.0003).
Longitudinal Pregnancy Replication Cohort
MMA concentrations are altered during pregnancy and in
newborns;41,42 therefore, replication of the influence of
HIBCH rs291466 on MMA concentration was tested in
samples from a longitudinal study of pregnant women
and their newborn offspring (Table 3). MMA concentration
distributions by HIBCH rs291466 genotype show signifi-
cantly different effects for each of three trimesters of preg-
nancy and for cord bloods (p < 8.0 3 1005 for each
maternal time point; p ¼ 0.0005 for cord bloods, Table
4). TT (Met/Met) homozygotes have the lowest median
MMA concentration, whereas CC (?/?) homozygotes
have the highest median MMA concentration, consistent
with the direction of effect originally observed in the dis-
covery cohort of young Irish adults.
Association of ACSF3 rs1054747 with log10-transformed
MMA values was not observed at any time point for these
pregnant women (14 weeks, p ¼ 0.721; 24 weeks, p ¼
0.671; 34 weeks, p ¼ 0.795). Interestingly, replication in
the cord blood samples yielded a borderline association
(p ¼ 0.051) with mean MMA levels increasing with the
number of A alleles at this locus (0.61 mM versus 0.46 mM016
Table 2. Subject Characteristics of the TUDA Replication Cohort, with Participants Grouped by HIBCH rs291466 Genotype
Characteristic
Alla CC (?/?) CT (?/Met) TT (Met/Met)
Kruskal-Wallis Testc
p ValueMedian (IQIb) Median (IQIb) Median (IQIb) Median (IQIb)
No. of Individuals 1,481 460 723 298 –
Sex (M/F) 493/991 168/293 231/494 94/204 –
Age (years) 79.0 (72.6–83.9) 79.5 (72.8–84.7) 78.6 (72.0–83.2) 78.9 (73.2–84.1) 0.285
Body Mass Index (kg/m2) 27.1 (23.6–30.8) 27.3 (23.6–31.0) 27.0 (23.8–30.6) 26.8 (23.6–30.6) 0.742
Creatinine (mmol/L) 82.0 (69–101) 82.0 (69.0–101) 82.0 (69.5–101) 81.0 (71.0–103) 0.878
Hemoglobin (g/dL) 12.8 (11.7–13.8) 12.8 (11.7–14.0) 12.8 (11.7–13.8) 12.7 (11.7–13.8) 0.630
Urea (mmol/L) 6.7 (5.4–8.7) 6.6 (5.4–8.8) 6.8 (5.4–8.7) 6.8 (5.5–8.7) 0.726
Serum cobalamin (pmol/L) 185 (131–287) 177 (128–274) 187 (135–286) 194 (128–307) 0.270
holoTC (pmol/L) 39.0 (25.8–57.0) 38.4 (25.6–55.0) 38.8 (25.9–57.5) 39.9 (25.8–60.9) 0.550
Homocysteine (mmol/L) 16.2 (13.0–20.5) 15.9 (12.5–19.7) 16.3 (13.2–20.9) 16.2 (13.3–20.3) 0.097
MMA (mmol/L) 0.34 (0.24–0.51) 0.42 (0.29–0.62) 0.33 (0.24–0.50) 0.26 (0.19–0.37) < 0.0001c
M, male; F, female.
aIQI (inter-quartile interval) represents the 25th–75th percentile.
bThe non-transformed data were compared with the Kruskal-Wallis one-way ANOVA by ranks for three or more independent groups; p<0.05 was considered
significant.
cThe association test for this SNP was also performed by simple linear regression with PLINK v.2 and under the assumption of an additive genetic model (number of
minor alleles: 0, 1, and 2). p ¼ 4.01 3 1026 was obtained for the unadjusted log10-transformed data.for AG and GG genotype groups, respectively), as origi-
nally observed.
Functional Studies
Because the signal associated with HIBCH rs291466 was
driven by a common allele in a gene previously unknown
to influence MMA and had the largest impact on MMA
levels, we pursued functional characterization studies.
Alterations of initiator methionine residues have been
associated with loss-of-function alleles.43–45 We assessed
the impact of this missense change on HIBCH (see below).
To determine whether HIBCH rs291466 influences the
expression of HIBCH mRNA, we analyzed RNA-seq data
generated from lymphoblastoid lines.39,46 In 211 HIBCH
rs291466 heterozygous individuals, 59% of the reads con-
tained the C (?) allele and 41% contained the T (Met) allele,
(p < 2.2 3 1012; Figure 3A). We then examined whether
absolute HIBCH mRNA expression changed depending
on HIBCH rs291466 genotype. The median mRNA expres-
sion scores of TT (Met/Met), TC (Met/?), and CC (?/?)
genotype groups increased from 10.2 to 11.3 to 13.0,
respectively (p < 5.02 3 1011, Figure 3B). No other gene
in a 1-megabase window around HIBCH had this
rs291466-dependent effect (data not shown). An indepen-
dent expression dataset40 confirmed these results (p <
3.87 3 1014; Figure 3C), indicating that the loss of the
initiating methionine is associated with an allele-specific
increase in HIBCH mRNA expression.
To test whether HIBCH levels differ between individuals
with HIBCH rs291466 homozygous genotypes, we ob-
tained lymphoblast cell lines derived from nine indi-
viduals with the TT (Met/Met) genotype or the CC (?/?)The Amgenotype. Immunoblot analysis, used to quantify HIBCH
levels, showed that cell lines with the CC (?/?) genotype
have higher steady-state levels of HIBCH than cell lines
with the TT (Met/Met) genotype (Figure 3D).Discussion
Three aspects of this GWAS of plasma MMA concentration
are particularly noteworthy. First, we report the strong
association of HIBCH rs291466 with MMA levels in a
young, healthy, ethnically homogeneous cohort from
Ireland, as well as its replication in two ethnically matched
Irish cohorts representing significantly different stages of
life. Second, the value of GWASs is emphasized given
that this study revealed that the largest genetic influ-
ence on MMA levels is not related to cobalamin meta-
bolism and is instead related to a little-studied pathway
involved in valine catabolism. Last, we note the potential
complexity of determining the mode of function of any
phenotype-associated variant, as shown by the unexpected
apparent mechanism through which the HIBCH rs291466
(p.Met1?) association signal achieves its effect on MMA
levels. In this case the variant associated with the strongest
GWAS signal would be expected to produce a null or hypo-
morphic allele, i.e., one that produces a protein that is not
properly targeted to the mitochondrion. Our experiments
reveal the opposite; the missense allele associated with
higher levels of MMA produces more mature enzyme and
acts at the level of mRNA. It is unclear whether this allele
directly influences transcription or whether this activity
resides with another linked SNP.erican Journal of Human Genetics 98, 869–882, May 5, 2016 875
Figure 2. Replication of the HIBCH
rs291466 Association with Plasma MMA
Concentration in the TUDA Cohort
The HIBCH rs291466 association
with plasma MMA concentrations was
confirmed in 1,481 older Irish adults in
the TUDA cohort.
(A) Plasma MMA concentration (mean
and 95% confidence interval) for each
HIBCH rs291466 genotype group in
older Irish adults sorted by glomerular
filtration rate (GFR), a measure of renal
function. GFR % 29 mL/min indicates
severely impaired renal function, GFR 30–
59 mL/min indicates moderately impaired
function, and GFRR 60 mL/min indicates
normal function.
(B) PlasmaMMA concentration (mean and
95% confidence interval) for each HIBCH
rs291466 genotype group in older Irish
adults sorted by age group.
(C) Plasma MMA levels plotted as a
function of serum holoTC levels in each
HIBCH rs291466 genotype group. HoloTC
data were categorized by groups in
ascending order of 10 pmol/L. Median
MMA values were calculated within each
grouped category. Line graphs were
plotted as median MMA against median
holoTC within each group.
(D) Plasma MMA levels plotted as func-
tion of serum cobalamin levels in each
HIBCH rs291466 genotype group. Cobal-
amin data were categorized by groups
in ascending order of 100 pmol/L. Median MMA values were calculated within each grouped category. Line graphs were plotted as
median MMA concentration against median cobalamin concentration within each group.The clinical utility of MMA concentration as a confir-
matory biomarker of cobalamin deficiency makes this
metabolite an important candidate for GWASs. Recent
GWAS results for cobalamin have reported a strong associ-
ation with fucosyltransferase 2 (FUT2 [MIM: 182100]), and
in several of these studies, MUT was also identified as a
significant determinant of cobalamin at a genome-wide
level.47–50 We observed no such associations in our
GWAS of MMA concentration, and the top MMA GWAS
result is in fact unrelated to cobalamin metabolism. This
is consistent with two mechanisms for elevated levels of
circulating MMA. First, a reduction in cobalamin reduces
activity of the MUT enzyme, resulting in accumulation of
MMA. Second, a cobalamin-independent mechanism of
increased flux through the valine catabolism pathway
(e.g., via increased levels of HIBCH due to the C [?] allele
of rs291466) can result in increased production of MMA.
The effect of the latter was not anticipated, but is very
strong.
Although HIBCH rs291466 is the more common
variant (frequency of allele associated with elevated
MMA: 0.57 versus 0.05) with greater impact on plasma
MMA concentration (contribution to variance: 9.1%
versus 2.2%), we also genotyped the top ACSF3 polymor-
phism (rs1054747) in our replication cohorts. ACSF3
rs1054747 was significantly associated with MMA levels
in the sample of ~1,400 older Irish adults, but not in our876 The American Journal of Human Genetics 98, 869–882, May 5, 2longitudinal pregnancy cohort (Table 4). The combination
of the low MAF and the substantially smaller sample size
(~180 pregnant women) most likely diminished our power
to detect the effect of this SNP on MMA levels. In support
of this, we note that their newborns did show a borderline
association (Table 4). ACSF3 rs1054747 was not found to
be associated with mRNA levels of ACSF3 by examination
of the Geuvadis RNA-seq data (Figure S5) or by querying
the GTEx Portal (over 30 tissues, v.6). This SNP, or the
causal variant linked to it, does not seem to act at the level
of transcription. However, there are pre-existing data
and biological arguments supporting the role of ACSF3
in MMA metabolism. First, the genome-wide signal in
ACSF3 confirms recent observations of mutations in this
gene as a cause of CMAMMA.4,5 Second, our observations
on this poorly understoodmember of the acyl CoA synthe-
tase family of enzymes reinforce the notion of a reversible
MMA shunt to provide R-MMACoA for the MUT reaction
through the deacetylation of S-MMACoA and subsequent
reacetylation of the free R-MMA, as described by Mont-
gomery et al.51 and supported by Alfares et al.4 Our data
further indicate that spontaneous racemization of free
MMA could make a more substantial contribution to the
pathway than hitherto supposed (see Figure 4) and adds
to the debate on whether a functional MMACoA epimerase
enzyme is critical for metabolism down this pathway.51,52
Our data and these biological observations confirm the016
Table 3. Subject Characteristics of the Longitudinal Pregnancy Replication Cohort at First Antenatal Clinic Visit, with Participants
Grouped by HIBCH rs291466 Genotype
Characteristic
All CC (?/?) CT (?/Met) TT (Met/Met)
Kruskal-Wallis Testb
p valueMedian (IQIa) Median (IQIa) Median (IQIa) Median (IQIa)
No. of Individuals 185 70 80 35 –
Age (y) 30.0 (25.0–33.0) 30.0 (26.5–34.0) 28.0 (25.0–31.0) 30.0 (25.0–32.0) 0.044
Body Mass Index (kg/m2) 24.8 (21.9–28.2) 25.9 (22.5–28.2) 24.3 (21.0–27.6) 24.8 (21.5–28.5) 0.292
Gestation (weeks) 14.2 (12.9–15.4) 14.0 (12.4–15.6) 14.1 (12.8–15.5) 13.9 (13.3–14.7) 0.914
Creatinine (mmol/L) 46.6 (42.4–51.3) 46.7 (42.4–51.9) 46.2 (42.4–50.7) 48.1 (42.9–51.3) 0.700
Serum cobalamin (pmol/L) 171 (120–215) 180 (133–225) 156 (108–205) 184 (140–217) 0.054
holoTC (pmol/L) 33.6 (24.7–43.7) 36.4 (27.5–46.4) 31.1 (21.7–39.4) 36.7 (25.2–43.7) 0.034
Homocysteine (mmol/L) 6.29 (5.35–7.34) 6.06 (5.06–7.27) 6.50 (5.51–7.63) 6.01 (5.27–7.47) 0.097
aIQI (inter-quartile interval) represents the 25th–75th percentile.
bThe non-transformed data were compared with the Kruskal-Wallis one-way ANOVA by ranks for three or more independent groups; p < 0.05 was considered
significant.connection between ACSF3 activity and steady-state levels
of MMA in plasma.
We also confirmed the association of MMA concentra-
tion and HIBCH rs291466. This SNP was not only the top
genome-wide association signal in a young, healthy Irish
cohort, it was also significant in an older Irish cross-
sectional cohort and in a longitudinal cohort of pregnant
Irish women and their newborns. The persistence of this
genetic effect is remarkable considering the known poten-
tial for altered MMA levels at each of these stages of life.
Maternal circulating cobalamin decreases over the course
of pregnancy as a result of hemodilution and other preg-
nancy related factors.41 This is accompanied by changes
in maternal plasma MMA concentration throughout preg-
nancy and in neonatal blood41,42 that could have obscured
the replication signal (Table 4). Similarly, in the sample of
older adults, the effect of HIBCH rs291466 on MMA con-
centration was detected despite the noise introduced by
the expected and observed (Table 2) age-related increase
in MMA levels as a result of factors such as impaired cobal-
amin absorption and decreased renal function. The ability
to detect the GWAS signal of HIBCH rs291466 in both




All CC (?/?) C
Median (IQIa) Median (IQIa) M
14 weeks (mmol/L) 0.15 (0.11–0.21), n ¼ 184 0.18 (0.13–0.25), n ¼ 69 0
24 weeks (mmol/L) 0.18 (0.14–0.25), n ¼ 132 0.23 (0.17–0.29), n ¼ 49 0
34 weeks (mmol/L) 0.21 (0.16–0.31), n ¼ 129 0.25 (0.19–0.36), n ¼ 48 0
Cord blood,
delivery (mmol/L)
0.40 (0.30–0.58), n ¼ 110 0.47 (0.30–0.67), n ¼ 43 0
aIQI (inter-quartile interval) represents the 25th–75th percentile.
bReplication was performed by simple linear regression of the unadjusted log10-tra
p < 0.05 was considered significant.
The Amvariant in the face of a phenotype with many known but
unaccounted confounders.
Our findings demonstrate that HIBCH rs291466 is an
important determinant of MMA status, regardless of age
or renal function and, as such, is relevant to clinical deter-
mination of cobalamin deficiency. Low serum cobalamin
concentrations are common in older persons, and it is
difficult to assess their clinical significance because the
classic symptoms of cobalamin deficiency are often absent
or are similar to a variety of disorders in elderly individuals.
MMA concentration is regarded as the most reliable
biochemical indicator of cobalamin deficiency and is used
as a confirmatory test when serum cobalamin or holoTC
concentrations are indeterminate and clinical symptoms
are unreliable.14,20,53 In our older replication cohort, the
median MMA concentration in CC (?/?) individuals was
0.42 mmol/L (Table 2). By the standard definition of abnor-
mally elevated MMA concentration (> 0.37 mmol/L), 58%
of CC (?/?) homozygotes would be considered cobalamin
deficient. Although holoTC concentration has been sug-
gested to be amore reliable marker of cobalamin deficiency
than serum total cobalamin,54,55 only half of these high-
MMA individuals (52%) would be regarded as having aReplication Cohort and in Cord Blood with Participants Grouped by
T (?/Met) TT (Met/Met)
Replication testb
p Valueedian (IQIa) Median (IQIa)
.15 (0.12–0.21), n ¼ 80 0.10 (0.08–0.14), n ¼ 35 1.95 3 108
.18 (0.15–0.25), n ¼ 53 0.14 (0.12–0.17), n ¼ 30 1.05 3 105
.21 (0.17–0.31), n ¼ 57 0.15 (0.14–0.20), n ¼ 24 7.39 3 105
.40 (0.34–0.58), n ¼ 49 0.26 (0.23–0.3), n ¼ 18 0.0005
nsformed data via PLINK v.2 and under the assumption of an additive genetic;
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Figure 3. Association of HIBCH rs291466
Genotype with HIBCH mRNA and Protein
Levels
(A) Relative amounts of HIBCH rs291466
mRNA isoforms expressed in heterozy-
gous individuals. The fraction of RNA-seq
reads for each HIBCH rs291466 allele
was calculated for 211 heterozygotes using
genotype and expression data from the
GEUVADIS RNA Sequencing Project, based
on the 1000Genomes EUR samples. Distri-
butions for each allele (T [Met] versus C [?])
are shown.
(B) HIBCH mRNA expression by rs291466
genotype (TT [Met/Met], TC [Met/?], and
CC [?/?]). Distribution of HIBCH RPKM
(reads per kilobase of transcript per million
reads mapped) scores for each HIBCH
rs291466 genotype group (100 TT [Met/Met], 211 TC [Met/?], and 151 CC [?/?]), based on 1000 Genomes EUR samples, is shown.
(C) Distribution of HIBCH expression scores by HIBCH rs291466 genotype groups (TT [Met/Met], TC [Met/?], and C [?/?]) for 219 indi-
viduals (CEU, YRI, JPT, CHB), based on data from the GTEx Project 3, v.2.
(D)Western blot analysis of HIBCH inHIBCH homozygotes (TT ([Met/Met] and CC [?/?]). Whole-cell lysates of nine independent Coriell
cell lines were immunoblotted for HIBCH as well as PCNA as a control (WB, western blot). Normalized signals (HIBCH/PCNA) for each
cell line are shown below the blot.possible deficiency (holoTC < 30 pmol/l). Thus, 28% of all
CC (?/?) individuals might be falsely classified as cobal-
amin deficient when using MMA values alone. In contrast,
amongTT (Met/Met) individuals, far fewer (25%) hadMMA
concentrations above 0.37 mmol/L, and the majority of
those with highMMA levels also had low cobalamin status
(73%) (holoTC < 30 pmol/L), consistent with a true cobal-
amin deficiency. Choosing other thresholds for total
cobalamin (110 pmol/L) or holoTC (35 pmol/L) changed
the proportion of individuals within deficient or sufficient
categories but did not remove the strong genotype effect.
Thus, this common HIBCH polymorphism is a cobalamin-
independent determinant of plasma MMA concentration
that influences its effectiveness as a cobalamin status indi-
cator inolder adultswhenapplying current clinical cut-offs.
The unanticipated discovery of a variant in HIBCH as a
strongly significant contributor to the variance of plasma
MMA concentration highlights this little-studied enzyme
of branched-chain amino acid metabolism that for several
decades has been cited as an unusual feature within the
valine oxidation pathway. b-oxidation of odd-chain fatty
acids, catabolism of branched-chain amino acids, and
metabolism of cholesterol side-chain moieties all follow
pathways that generate methylmalonyl-CoA, with coen-
zyme A (CoA) being added early in the catabolic process.
Unlike leucine and isoleucine, valine degradation contains
a unique intermediate step, carried out by mitochondrial
HIBCH, whereby CoA is removed from 3-hydroxyisobu-
tyryl-CoA, producing 3-hydroxyisobutyric acid, an easily
diffusible free acid. Two steps later, CoA is reintroduced
when methylmalonic semialdehyde is converted to pro-
pionyl-CoA (Figure 4). HIBCH is reported to be abundant
in human liver and might be important to remove the pre-
ceding toxic intermediate, methacrylyl-CoA.56,57 Animal
studies also suggest that release of the HIBCH product,
3-hydroxybutyric acid, might be a mechanism to conserve878 The American Journal of Human Genetics 98, 869–882, May 5, 2the gluconeogenic potential of valine.58 Severe mutations
in HIBCH are extremely rare and all reported affected chil-
dren have died early in life.59,60
What are the consequences of this common but previ-
ously unstudied polymorphism? It is possible that the
reduced amount of HIBCH enzyme produced by themethi-
onine-encoding allele causes a decreasedfluxof 3-hydroxyi-
sobutyryl-CoA through HIBCH, perhaps leading to higher
mitochondrial concentrations of upstream intermediates
andmoderately altered C4-hydroxy carnitines in the blood
of TT (Met/Met) individuals. This model is consistent with
what is observed in subjects with rare severe mutations in
this enzyme.59,61 Methacrylyl-CoA, an intermediate com-
pound in valine catabolism, is highly reactive and forms
toxic conjugates with cysteine.62 The concentration of
this compound might be increased when HIBCH activity
is low (such as T [Met] homozygotes compared to C [?]
homozygotes). Higher concentrations of methacrylyl-CoA
within mitochondria could inhibit enzymes involved in
oxidative phosphorylation.59 It is also possible that the
methionine-encoding allele results in a less efficient gluco-
neogenic system. We did not measure these metabolites,
and we did not detect any consistent changes in liver func-
tion tests by genotype in our discovery or our replication
cohort of older adults (Tables 1 and 2). Additional studies
of the phenotypic andmetabolic consequences of this poly-
morphism are warranted. No other phenotypes have been
reported to be associated with HIBCH or ACSF3 in the
GWAS catalog. Recently, Raffler and colleagues reported an
associationbetweenvariation inHIBCH andanunidentified
compound in urine.63 We anticipate that this compound
will be a clearedderivativeof valine catabolism.Theabsence
of any known associations between these two loci and re-
ported phenotypes might mean that elevated MMA levels
in general do not directly contribute to disease, but rather
report on its presence or its potential to develop.016
Figure 4. The Valine Catabolism
Pathway
All branched-chain amino acids (BCAAs)
are first transaminated to the 2-oxo deriva-
tive via branched-chain aminotransferase
(BCAT). The oxo-derivatives then undergo
irreversible oxidative decarboxylation to
a CoA ester derivative. In the case of valine,
this produces isobutyryl-CoA, which is
converted tomethacrylyl-CoA, an interme-
diate that is regarded as highly reactive
and potentially toxic within mitochon-
dria. Next, methacrylyl CoA is hydrated
via crotonase (methacrylyl-CoA hydratase)
to form 3-hydroxyisobutyryl-CoA. In the
following step, unique to valine meta-
bolism, the CoA is removed to form 3-hy-
droxyisobutyric acid, a molecule that is
easily diffusible across the mitochon-
drial membrane. The reaction is catalyzed
by HIBCH. 3-hydroxyisobutyric acid is
subsequently converted to methylmalonic
semialdehyde, and in the next step, CoA is
reinstated in the pathway by the oxidative
decarboxylation of methylmalonic semi-
aldehyde to propionyl-CoA. Further catabo-
lism of propionyl-CoA through cobalamin-
dependent methylmalonyl-CoA mutase
(MUT) is common to other BCAAs, odd-chain fatty acids, cholesterol, etc. An epimerase enzyme converts S-methylmalonyl-CoA
(S-MMA-CoA) to R-MMA-CoA, the epimer used in theMUT reaction. AMMA shunt has been proposedwhereby a deacetylation- reacetyla-
tionstep, catalyzedby themalonyl andMMA-specificAcylCoAsynthetaseACSF3produces freeMMA,whichcanundergo spontaneous race-
mization and be re-acetylated in the R-MMA-CoA form.Beyond the impact of this SNP, the mechanism of
action of the HIBCH rs291466 signal requires elucidation.
Although T (Met) is the minor allele for HIBCH rs291466
in this Irish population, phylogenetic analysis suggests
that it is likely to be the ancestral allele. T (Met) is also
the major allele in the publicly genotyped HapMap
CHB, JPT, and YRI samples. The derived C (?) allele results
in higher MMA concentrations. Given that MMA is a
downstream product of valine catabolism, our metabolic
results suggest that the resulting enzyme is more active
or more abundant. Because this polymorphism is located
at the start of the mitochondrial leader sequence, it might
alter the efficiency at which the protein is imported into
mitochondria. We tested this model in cell culture studies.
Both isoforms of the enzyme were equally efficiently
translocated into the mitochondrial matrix (Figure S4).
These results suggest that a downstream methionine
residue is used to initiate translation and the shortened
leader efficiently directs mitochondrial import. Lympho-
blastoid RNA-seq data and expression quantitative trait
loci (eQTL) analysis demonstrated that, compared to the
T (Met) allele, the C (?) allele is associated with a signifi-
cant increase of HIBCH mRNA levels, presumably result-
ing in the increased enzyme concentrations that we
observed in cultured lymphoblastoid cells. This effect is
observed in eQTL analysis (p < 5.5 3 1006) of more
than 30 tissue types, including liver (GTEx Portal, v.6).
On the basis of the genetic code alone, it is predicted
that the loss of the initiating methionine would alter
HIBCH function via translation or at the level of the pro-The Amduced protein. However, our data support the conclusion
that it is likely that this SNP or another variant linked to it
produces the metabolic phenotype by influencing mRNA
transcription or stability. There are 33 SNPs in strong LD
with HIBCH rs291466 (r2 > 0.95 in the EUR cohort), all
of which are intronic or 50 of the transcriptional start
site and reside in an area containing chromatin marks
consistent with active transcription. Further study is
required to determine the identity and mechanism of
the functional variant underlying the HIBCH rs291466
association with MMA levels.
In conclusion, we have identified two genetic loci that
significantly affect the plasma concentration of MMA.
These loci provide important data underpinning the cur-
rent understanding of the pathways leading to MMA pro-
duction. Our data suggest that genetic variation in HIBCH
might be especially relevant in situations where protein
catabolism is elevated, i.e., states of acute disease and in
the elderly.Accession Numbers
The accession number for the TSS genotype and phenotype data
reported in this paper is dbGAP: phs000789.v1.p1.Supplemental Data
Supplemental Data include five figures and two tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
2016.03.005.erican Journal of Human Genetics 98, 869–882, May 5, 2016 879
Acknowledgments
The authors acknowledge the contributions made by the partici-
pants in the Trinity Student Study, the Trinity Ulster Department
of Agriculture study, and the longitudinal pregnancy study. The
TSS GWAS work was supported in part by the Intramural Research
Programs of the National Human Genome Research Institute
(NHGRI), the Eunice Kennedy Shriver National Institute of Child
Health and Human Development of the NIH, and the Health
Research Board, Dublin. This study utilized the high-performance
computational capabilities of the Biowulf Linux cluster at the
NIH (https://hpc.nih.gov/systems). C.D.C. is the recipient of an
NHGRI Health Disparities Research Fellowship. The TUDA study
was funded by the Irish Department of Agriculture, Food and
the Marine’s Food Institutional Research Measure initiative and
the Northern Ireland Department for Employment and Learning
under the Cross-Border Research and Development Programme
‘‘Strengthening the all-Island Research Base.’’ Holotranscobalamin
and methylmalonic acid measurements in the TUDA cohort were
sponsored by Axis-Shield Diagnostics.
Received: August 12, 2015
Accepted: March 8, 2016
Published: April 28, 2016Web Resources
dbGaP, http://www.ncbi.nlm.nih.gov/gap
GenBank, http://www.ncbi.nlm.nih.gov/genbank/
Geuvadis RNA Sequencing Project, http://www.geuvadis.org/web/
geuvadis/RNAseq-project
GWAS Catalog v.1.0.1, accessed February 2, 2016, http://www.ebi.
ac.uk/gwas/
International HapMap GTEx Portal, http://www.gtexportal.org/
home/
Internation HapMap Project, http://hapmap.ncbi.nlm.nih.gov/
OMIM, http://www.omim.org/References
1. Ludwig, M.L., andMatthews, R.G. (1997). Structure-based per-
spectives on B12-dependent enzymes. Annu. Rev. Biochem.
66, 269–313.
2. Banerjee, R., and Chowdhury, S. (1999). Methylmalonyl-CoA
mutase. In Chemistry and Biochemistry of B12, R. Banerjee,
ed. (New York: John Wiley & Sons, Inc), pp. 707–729.
3. Marcadier, J.L., Smith, A.M., Pohl, D., Schwartzentruber, J.,
Al-Dirbashi, O.Y., Majewski, J., Ferdinandusse, S., Wanders,
R.J., Bulman, D.E., Boycott, K.M., et al.; FORGE Canada Con-
sortium (2013). Mutations in ALDH6A1 encoding methyl-
malonate semialdehyde dehydrogenase are associated with
dysmyelination and transient methylmalonic aciduria. Or-
phanet J. Rare Dis. 8, 98.
4. Alfares, A., Nunez, L.D., Al-Thihli, K., Mitchell, J., Melanc¸on,
S., Anastasio, N., Ha, K.C., Majewski, J., Rosenblatt, D.S., and
Braverman, N. (2011). Combined malonic and methylma-
lonic aciduria: exome sequencing reveals mutations in the
ACSF3 gene in patients with a non-classic phenotype.
J. Med. Genet. 48, 602–605.
5. Sloan, J.L., Johnston, J.J., Manoli, I., Chandler, R.J., Krause, C.,
Carrillo-Carrasco, N., Chandrasekaran, S.D., Sysol, J.R.,
O’Brien, K., Hauser, N.S., et al.; NIH Intramural Sequencing880 The American Journal of Human Genetics 98, 869–882, May 5, 2Center Group (2011). Exome sequencing identifies ACSF3 as
a cause of combined malonic and methylmalonic aciduria.
Nat. Genet. 43, 883–886.
6. Valayannopoulos, V., Haudry, C., Serre, V., Barth, M., Bod-
daert, N., Arnoux, J.B., Cormier-Daire, V., Rio, M., Rabier, D.,
Vassault, A., et al. (2010). New SUCLG1 patients expanding
the phenotypic spectrum of this rare cause of mild methylma-
lonic aciduria. Mitochondrion 10, 335–341.
7. Baik, H.W., and Russell, R.M. (1999). Vitamin B12 deficiency
in the elderly. Annu. Rev. Nutr. 19, 357–377.
8. Allen, L.H. (2009). How common is vitamin B-12 deficiency?
Am. J. Clin. Nutr. 89, 693S–696S.
9. Johnson, M.A., Hawthorne, N.A., Brackett, W.R., Fischer, J.G.,
Gunter, E.W., Allen, R.H., and Stabler, S.P. (2003). Hyperho-
mocysteinemia and vitamin B-12 deficiency in elderly using
Title IIIc nutrition services. Am. J. Clin. Nutr. 77, 211–220.
10. Lindenbaum, J., Rosenberg, I.H., Wilson, P.W., Stabler, S.P.,
and Allen, R.H. (1994). Prevalence of cobalamin deficiency
in the Framingham elderly population. Am. J. Clin. Nutr. 60,
2–11.
11. Pennypacker, L.C., Allen, R.H., Kelly, J.P., Matthews, L.M.,
Grigsby, J., Kaye, K., Lindenbaum, J., and Stabler, S.P. (1992).
High prevalence of cobalamin deficiency in elderly outpa-
tients. J. Am. Geriatr. Soc. 40, 1197–1204.
12. Reynolds, E. (2006). Vitamin B12, folic acid, and the nervous
system. Lancet Neurol. 5, 949–960.
13. Stabler, S.P., Lindenbaum, J., and Allen, R.H. (1996). The use of
homocysteine and other metabolites in the specific diagnosis
of vitamin B-12 deficiency. J. Nutr. 126 (4, Suppl), 1266S–
1272S.
14. Savage, D.G., Lindenbaum, J., Stabler, S.P., and Allen, R.H.
(1994). Sensitivity of serummethylmalonic acid and total ho-
mocysteine determinations for diagnosing cobalamin and
folate deficiencies. Am. J. Med. 96, 239–246.
15. Morris, M.S., Jacques, P.F., Rosenberg, I.H., and Selhub, J.
(2002). Elevated serum methylmalonic acid concentrations
are common among elderly Americans. J. Nutr. 132, 2799–
2803.
16. Vogiatzoglou, A., Oulhaj, A., Smith, A.D., Nurk, E., Drevon,
C.A., Ueland, P.M., Vollset, S.E., Tell, G.S., and Refsum, H.
(2009). Determinants of plasmamethylmalonic acid in a large
population: implications for assessment of vitamin B12 status.
Clin. Chem. 55, 2198–2206.
17. Bailey, R.L., Durazo-Arvizu, R.A., Carmel, R., Green, R.,
Pfeiffer, C.M., Sempos, C.T., Carriquiry, A., and Yetley, E.A.
(2013). Modeling a methylmalonic acid-derived change point
for serum vitamin B-12 for adults in NHANES. Am. J. Clin.
Nutr. 98, 460–467.
18. Bailey, R.L., Carmel, R., Green, R., Pfeiffer, C.M., Cogswell,
M.E., Osterloh, J.D., Sempos, C.T., and Yetley, E.A. (2011).
Monitoring of vitamin B-12 nutritional status in the United
States by using plasma methylmalonic acid and serum
vitamin B-12. Am. J. Clin. Nutr. 94, 552–561.
19. Sobczynska-Malefora, A., Gorska, R., Pelisser, M., Ruwona, P.,
Witchlow, B., and Harrington, D.J. (2014). An audit of holo-
transcobalamin (‘‘Active’’ B12) andmethylmalonic acid assays
for the assessment of vitamin B12 status: application in a
mixed patient population. Clin. Biochem. 47, 82–86.
20. Clarke, R., Refsum, H., Birks, J., Evans, J.G., Johnston, C., Sher-
liker, P., Ueland, P.M., Schneede, J., McPartlin, J., Nexo, E., and
Scott, J.M. (2003). Screening for vitamin B-12 and folate defi-
ciency in older persons. Am. J. Clin. Nutr. 77, 1241–1247.016
21. Hølleland, G., Schneede, J., Ueland, P.M., Lund, P.K., Refsum,
H., and Sandberg, S. (1999). Cobalamin deficiency in general
practice. Assessment of the diagnostic utility and cost-benefit
analysis of methylmalonic acid determination in relation to
current diagnostic strategies. Clin. Chem. 45, 189–198.
22. Molloy, A.M., Kirke, P.N., Brody, L.C., Scott, J.M., and Mills,
J.L. (2008). Effects of folate and vitamin B12 deficiencies dur-
ing pregnancy on fetal, infant, and child development. Food
Nutr. Bull. 29, S101–S115.
23. Bjørke Monsen, A.L., and Ueland, P.M. (2003). Homocysteine
and methylmalonic acid in diagnosis and risk assessment
from infancy to adolescence. Am. J. Clin. Nutr. 78, 7–21.
24. Desch, K.C., Ozel, A.B., Siemieniak, D., Kalish, Y., Shavit, J.A.,
Thornburg, C.D., Sharathkumar, A.A., McHugh, C.P., Laurie,
C.C., Crenshaw, A., et al. (2013). Linkage analysis identifies
a locus for plasma von Willebrand factor undetected by
genome-wide association. Proc. Natl. Acad. Sci. USA 110,
588–593.
25. Mills, J.L., Carter, T.C., Scott, J.M., Troendle, J.F., Gibney, E.R.,
Shane, B., Kirke, P.N., Ueland, P.M., Brody, L.C., and Molloy,
A.M. (2011). Do high blood folate concentrations exacerbate
metabolic abnormalities in people with low vitamin B-12
status? Am. J. Clin. Nutr. 94, 495–500.
26. Carter, T.C., Pangilinan, F., Molloy, A.M., Fan, R., Wang, Y.,
Shane, B., Gibney, E.R., Midttun, Ø., Ueland, P.M., Cropp,
C.D., et al. (2015). Common Variants at Putative Regulatory
Sites of the Tissue Nonspecific Alkaline Phosphatase Gene
Influence Circulating Pyridoxal 50-Phosphate Concentration
in Healthy Adults. J. Nutr. 145, 1386–1393.
27. Laird, E., McNulty, H., Ward, M., Hoey, L., McSorley, E., Wal-
lace, J.M., Carson, E., Molloy, A.M., Healy, M., Casey, M.C.,
et al. (2014). Vitamin D deficiency is associated with inflam-
mation in older Irish adults. J. Clin. Endocrinol. Metab. 99,
1807–1815.
28. Windelberg, A., Arseth, O., Kvalheim, G., and Ueland, P.M.
(2005). Automated assay for the determination of methylma-
lonic acid, total homocysteine, and related amino acids in
human serum or plasma by means of methylchloroformate
derivatization and gas chromatography-mass spectrometry.
Clin. Chem. 51, 2103–2109.
29. Kelleher, B.P., Walshe, K.G., Scott, J.M., and O’Broin, S.D.
(1987). Microbiological assay for vitamin B12 with use of a
colistin-sulfate-resistant organism. Clin. Chem. 33, 52–54.
30. Brady, J., Wilson, L., McGregor, L., Valente, E., and Orning, L.
(2008). Active B12: a rapid, automated assay for holotranscoba-
laminon theAbbottAxSYManalyzer.Clin.Chem.54, 567–573.
31. Lonati, S., Novembrino, C., Ippolito, S., Accinni, R., Galli, C.,
Troonen, H., Campolo, J., Della Noce, C., Lunghi, G., and
Catena, F.B. (2004). Analytical performance and method
comparison study of the total homocysteine fluorescence po-
larization immunoassay (FPIA) on the AxSYM analyzer. Clin.
Chem. Lab. Med. 42, 228–234.
32. Rasmussen, K., Møller, J., Ostergaard, K., Kristensen, M.O.,
and Jensen, J. (1990). Methylmalonic acid concentrations in
serum of normal subjects: biological variability and effect of
oral L-isoleucine loads before and after intramuscular admin-
istration of cobalamin. Clin. Chem. 36, 1295–1299.
33. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.The Am34. Patterson, N., Price, A.L., and Reich, D. (2006). Population
structure and eigenanalysis. PLoS Genet. 2, e190.
35. Barrett, J.C., Fry, B., Maller, J., and Daly, M.J. (2005). Haplo-
view: analysis and visualization of LD and haplotype maps.
Bioinformatics 21, 263–265.
36. Laurie, C.C., Doheny, K.F., Mirel, D.B., Pugh, E.W., Bierut, L.J.,
Bhangale, T., Boehm, F., Caporaso, N.E., Cornelis, M.C., Eden-
berg, H.J., et al.; GENEVA Investigators (2010). Quality control
and quality assurance in genotypic data for genome-wide
association studies. Genet. Epidemiol. 34, 591–602.
37. Li, Y., Willer, C.J., Ding, J., Scheet, P., and Abecasis, G.R.
(2010). MaCH: using sequence and genotype data to estimate
haplotypes and unobserved genotypes. Genet. Epidemiol. 34,
816–834.
38. Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P.,
Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L.,
and Parkinson, H. (2014). The NHGRI GWAS Catalog, a
curated resource of SNP-trait associations. Nucleic Acids Res.
42, D1001–D1006.
39. Lappalainen, T., Sammeth,M., Friedla¨nder, M.R., ’t Hoen, P.A.,
Monlong, J., Rivas, M.A., Gonza`lez-Porta, M., Kurbatova, N.,
Griebel, T., Ferreira, P.G., et al.; Geuvadis Consortium (2013).
Transcriptome and genome sequencing uncovers functional
variation in humans. Nature 501, 506–511.
40. Consortium, G.; GTEx Consortium (2013). The Genotype-
Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585.
41. Murphy, M.M., Molloy, A.M., Ueland, P.M., Fernandez-Ballart,
J.D., Schneede, J., Arija, V., and Scott, J.M. (2007). Longitudi-
nal study of the effect of pregnancy on maternal and fetal
cobalamin status in healthy women and their offspring.
J. Nutr. 137, 1863–1867.
42. Bjørke Monsen, A.L., Ueland, P.M., Vollset, S.E., Guttormsen,
A.B., Markestad, T., Solheim, E., and Refsum, H. (2001). Deter-
minants of cobalamin status in newborns. Pediatrics 108,
624–630.
43. Akizu, N., Shembesh, N.M., Ben-Omran, T., Bastaki, L., Al-Ta-
wari, A., Zaki, M.S., Koul, R., Spencer, E., Rosti, R.O., Scott, E.,
et al. (2013). Whole-exome sequencing identifies mutated
c12orf57 in recessive corpus callosum hypoplasia. Am. J.
Hum. Genet. 92, 392–400.
44. Ramalho, A.S., Lewandowska, M.A., Farinha, C.M., Mendes,
F., Gonc¸alves, J., Barreto, C., Harris, A., and Amaral, M.D.
(2009). Deletion of CFTR translation start site reveals func-
tional isoforms of the protein in CF patients. Cell. Physiol.
Biochem. 24, 335–346.
45. Van Hove, J.L., Saenz, M.S., Thomas, J.A., Gallagher, R.C.,
Lovell, M.A., Fenton, L.Z., Shanske, S., Myers, S.M., Wanders,
R.J., Ruiter, J., et al. (2010). Succinyl-CoA ligase deficiency: a
mitochondrial hepatoencephalomyopathy. Pediatr. Res. 68,
159–164.
46. Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Dur-
bin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T., and
McVean, G.A.; 1000 Genomes Project Consortium (2012).
An integrated map of genetic variation from 1,092 human
genomes. Nature 491, 56–65.
47. Hazra, A., Kraft, P., Selhub, J., Giovannucci, E.L., Thomas, G.,
Hoover, R.N., Chanock, S.J., and Hunter, D.J. (2008). Com-
mon variants of FUT2 are associated with plasma vitamin
B12 levels. Nat. Genet. 40, 1160–1162.
48. Tanaka, T., Scheet, P., Giusti, B., Bandinelli, S., Piras, M.G.,
Usala, G., Lai, S., Mulas, A., Corsi, A.M., Vestrini, A., et al.
(2009).Genome-wide association studyof vitaminB6, vitaminerican Journal of Human Genetics 98, 869–882, May 5, 2016 881
B12, folate, and homocysteine blood concentrations. Am. J.
Hum. Genet. 84, 477–482.
49. Grarup, N., Sulem, P., Sandholt, C.H., Thorleifsson, G., Ahlu-
walia, T.S., Steinthorsdottir, V., Bjarnason, H., Gudbjartsson,
D.F., Magnusson, O.T., Sparsø, T., et al. (2013). Genetic archi-
tecture of vitamin B12 and folate levels uncovered applying
deeply sequenced large datasets. PLoS Genet. 9, e1003530.
50. Lin, X., Lu, D., Gao, Y., Tao, S., Yang, X., Feng, J., Tan, A.,
Zhang, H., Hu, Y., Qin, X., et al. (2012). Genome-wide associ-
ation study identifies novel loci associated with serum level of
vitamin B12 in Chinese men. Hum. Mol. Genet. 21, 2610–
2617.
51. Montgomery, J.A., Mamer, O.A., and Scriver, C.R. (1983).
Metabolism of methylmalonic acid in rats. Is methylma-
lonyl-coenzyme a racemase deficiency symptomatic in man?
J. Clin. Invest. 72, 1937–1947.
52. Gradinger, A.B., Be´lair, C., Worgan, L.C., Li, C.D., Lavalle´e, J.,
Roquis, D., Watkins, D., and Rosenblatt, D.S. (2007). Atypical
methylmalonic aciduria: frequency of mutations in the meth-
ylmalonyl CoA epimerase gene (MCEE). Hum. Mutat. 28,
1045.
53. Carmel, R. (2011). Biomarkers of cobalamin (vitaminB-12) sta-
tus in the epidemiologic setting: a critical overview of context,
applications, and performance characteristics of cobalamin,
methylmalonic acid, and holotranscobalamin II. Am. J. Clin.
Nutr. 94, 348S–358S.
54. Valente, E., Scott, J.M., Ueland, P.M., Cunningham, C., Casey,
M., andMolloy, A.M. (2011). Diagnostic accuracy of holotran-
scobalamin, methylmalonic acid, serum cobalamin, and other
indicators of tissue vitamin B12 status in the elderly. Clin.
Chem. 57, 856–863.
55. Herrmann, W., Obeid, R., Schorr, H., and Geisel, J. (2005).
The usefulness of holotranscobalamin in predicting vitamin
B12 status in different clinical settings. Curr. Drug Metab. 6,
47–53.
56. Taniguchi, K., Nonami, T., Nakao, A., Harada, A., Kurokawa,
T., Sugiyama, S., Fujitsuka, N., Shimomura, Y., Hutson, S.M.,882 The American Journal of Human Genetics 98, 869–882, May 5, 2Harris, R.A., and Takagi, H. (1996). The valine catabolic
pathway in human liver: effect of cirrhosis on enzyme activ-
ities. Hepatology 24, 1395–1398.
57. Shimomura, Y., Murakami, T., Fujitsuka, N., Nakai, N., Sato, Y.,
Sugiyama, S., Shimomura, N., Irwin, J., Hawes, J.W., and
Harris, R.A. (1994). Purification and partial characterization
of 3-hydroxyisobutyryl-coenzyme A hydrolase of rat liver.
J. Biol. Chem. 269, 14248–14253.
58. Letto, J., Brosnan, M.E., and Brosnan, J.T. (1986). Valine
metabolism. Gluconeogenesis from 3-hydroxyisobutyrate.
Biochem. J. 240, 909–912.
59. Ferdinandusse, S., Waterham, H.R., Heales, S.J., Brown, G.K.,
Hargreaves, I.P., Taanman, J.W., Gunny, R., Abulhoul, L.,Wan-
ders, R.J., Clayton, P.T., et al. (2013). HIBCH mutations can
cause Leigh-like disease with combined deficiency of multiple
mitochondrial respiratory chain enzymes and pyruvate dehy-
drogenase. Orphanet J. Rare Dis. 8, 188.
60. Loupatty, F.J., Clayton, P.T., Ruiter, J.P., Ofman, R., Ijlst, L.,
Brown, G.K., Thorburn, D.R., Harris, R.A., Duran,M., Desousa,
C., et al. (2007). Mutations in the gene encoding 3-hydroxyi-
sobutyryl-CoA hydrolase results in progressive infantile neu-
rodegeneration. Am. J. Hum. Genet. 80, 195–199.
61. Peters, H., Ferdinandusse, S., Ruiter, J.P., Wanders, R.J., Boneh,
A., and Pitt, J. (2015). Metabolite studies in HIBCH and ECHS1
defects: Implications for screening. Mol. Genet. Metab. 115,
168–173.
62. Brown, G.K., Hunt, S.M., Scholem, R., Fowler, K., Grimes, A.,
Mercer, J.F., Truscott, R.M., Cotton, R.G., Rogers, J.G., and
Danks, D.M. (1982). beta-hydroxyisobutyryl coenzyme A de-
acylase deficiency: a defect in valine metabolism associated
with physical malformations. Pediatrics 70, 532–538.
63. Raffler, J., Friedrich, N., Arnold, M., Kacprowski, T., Rueedi, R.,
Altmaier, E., Bergmann, S., Budde, K., Gieger, C., Homuth, G.,
et al. (2015). Genome-Wide Association Study with Targeted
and Non-targeted NMR Metabolomics Identifies 15 Novel
Loci of Urinary Human Metabolic Individuality. PLoS Genet.
11, e1005487.016
